Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fred Saad

Showing results (901-910 of 993) with videos related to

Pageof 100
Sort By:
The Lancet. Oncology|February 11, 2019
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trialMatthew Smith, Chris Parker, Fred Saad, et al.
Urologic Oncology|March 7, 2023
Adenocarcinoma of the Bladder: Assessment of Survival Advantage Associated With Radical Cystectomy and Comparison With Urothelial Bladder CancerStefano Tappero, Francesco Barletta, Mattia Luca Piccinelli, et al.
Surgical Oncology|February 15, 2024
Differences in other-cause mortality in metastatic renal cell carcinoma according to partial vs. radical nephrectomy and age: A propensity score matched studyCarolin Siech, Reha-Baris Incesu, Simone Morra, et al.
European Urology Open Science|August 2, 2021
Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi)Herjan J T Coelingh Bennink, Jeroen A van Moorselaar, E David Crawford, et al.
European Urology Focus|April 6, 2023
Development and External Validation of a Novel Nomogram Predicting Cancer-specific Mortality-free Survival in Surgically Treated Papillary Renal Cell Carcinoma PatientsMattia Luca Piccinelli, Francesco Barletta, Stefano Tappero, et al.
Clinical Genitourinary Cancer|October 8, 2025
Rates of Secondary Bladder and Rectal Cancers After External Beam Radiation for Prostate Cancer According to Age and D'amico Risk Groups in A Contemporary CohortMario de Angelis, Carolin Siech, Letizia Maria Ippolita Jannello, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|April 10, 2025
Impact of ISUP grade group on cancer-specific mortality in radical prostatectomy-treated prostate cancer patients with organ-confined diseaseFrancesco Barletta, Stefano Tappero, Simone Morra, et al.
World Journal of Urology|August 8, 2025
Contemporary rates and predictors of prolonged hospital stay after radical cystectomy: a population-based analysisNatali Rodriguez Peñaranda, Fabian Falkenbach, Andrea Marmiroli, et al.
Scientific Reports|January 6, 2025
Use of inpatient palliative care in metastatic testicular cancer patients undergoing critical care therapy: insights from the national inpatient sampleCristina Cano Garcia, Reha-Baris Incesu, Francesco Barletta, et al.
Endocrine-Related Cancer|February 16, 2024
Multivariable model versus AJCC staging system: cancer-specific survival predictions in adrenocortical carcinomaLetizia Maria Ippolita Jannello, Simone Morra, Lukas Scheipner, et al.
Pageof 100

Showing results (901-910 of 993) with videos related to

Sort By:
Pageof 100
The Lancet. Oncology|February 11, 2019
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trialMatthew Smith, Chris Parker, Fred Saad, et al.
Urologic Oncology|March 7, 2023
Adenocarcinoma of the Bladder: Assessment of Survival Advantage Associated With Radical Cystectomy and Comparison With Urothelial Bladder CancerStefano Tappero, Francesco Barletta, Mattia Luca Piccinelli, et al.
Surgical Oncology|February 15, 2024
Differences in other-cause mortality in metastatic renal cell carcinoma according to partial vs. radical nephrectomy and age: A propensity score matched studyCarolin Siech, Reha-Baris Incesu, Simone Morra, et al.
European Urology Open Science|August 2, 2021
Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi)Herjan J T Coelingh Bennink, Jeroen A van Moorselaar, E David Crawford, et al.
European Urology Focus|April 6, 2023
Development and External Validation of a Novel Nomogram Predicting Cancer-specific Mortality-free Survival in Surgically Treated Papillary Renal Cell Carcinoma PatientsMattia Luca Piccinelli, Francesco Barletta, Stefano Tappero, et al.
Clinical Genitourinary Cancer|October 8, 2025
Rates of Secondary Bladder and Rectal Cancers After External Beam Radiation for Prostate Cancer According to Age and D'amico Risk Groups in A Contemporary CohortMario de Angelis, Carolin Siech, Letizia Maria Ippolita Jannello, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|April 10, 2025
Impact of ISUP grade group on cancer-specific mortality in radical prostatectomy-treated prostate cancer patients with organ-confined diseaseFrancesco Barletta, Stefano Tappero, Simone Morra, et al.
World Journal of Urology|August 8, 2025
Contemporary rates and predictors of prolonged hospital stay after radical cystectomy: a population-based analysisNatali Rodriguez Peñaranda, Fabian Falkenbach, Andrea Marmiroli, et al.
Scientific Reports|January 6, 2025
Use of inpatient palliative care in metastatic testicular cancer patients undergoing critical care therapy: insights from the national inpatient sampleCristina Cano Garcia, Reha-Baris Incesu, Francesco Barletta, et al.
Endocrine-Related Cancer|February 16, 2024
Multivariable model versus AJCC staging system: cancer-specific survival predictions in adrenocortical carcinomaLetizia Maria Ippolita Jannello, Simone Morra, Lukas Scheipner, et al.
Pageof 100